Conference Series


Journal Club 2019

  • Beta-Amyloid peptides enhance a-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and  Parkinson’s disease

Presented by Peter Kunach on 2019-01-23

Presentation Slides

  • White Matter Alterations and Cognitive Loss in Frontotemporal Dementia

Presented by Melissa Savard on 2019-02

Presentation Slides

  • PET Imaging, But not Clinical Phenotypes, Differentiate Tangle Predominant Dementia from Alzheimer’s Disease: A Machine Learning Study

Presented by Andrea Benedet on 2019-03-20

Presentation Slides

  • Gut Microbiome Alterations in Alzheimer Disease

Presented by Ellie Joung – 2019-04-03

Presentation Slides

  • Intrinsic Brain Connectivity Provides Scaffold for Tau Propagation in Alzheimer’s Disease

Presented by Joe Therriault – 2019-04-14

Presentation Slides

  • Feasibility of quantifying in vivo Tauopathy of Myotonic Dystrophy Type 1: a pilot study

Presented by Marlee Parsons – 2019-06-19

Presentation Slides

  • Implications of Plasma Biomarkers in the Management of Patients with MC

Presented by Lorenzo Bresciani – 2019-09-11

Presentation Slides

  • Influence of Insulin Resistance on Neural Function and Hippocampal Atrophy in Alzheimer Disease

Presented by Tina Wang – 2019-09-25

Presentation Slides

Protected: Dr. Pedro Rosa-Neto; June 21st, 2017 – 52nd CSFN

AAIC 2017 London:

  • Elevated CSF levels of neurofilament light chain is associated with gray matter neurodegeneration in both humans and transgenic rat model of Alzheimer’s disease

– Monica Shin, MSc

 

  • PET tau and amyloid synergy in default mode network determines clinical status in early phases of Alzheimer’s disease.

    Global and regional amyloid independently impair the DMN leading to cognitive decline

  • Voxel-wise determination of sensitivity, specificity, and thresholds for amyloid positivity using [18F]Florbetapir PET

  • Voxel-based power calculation and thresholds predictive of imminent neurodegeneration for preclinical Alzheimer’s disease clinical trials

– Tharick A. Pascoal, MD

 

  • Interaction between NEFL and APOE genes confers vulnerability to neurodegeneration

– Andrea L. Benedet, MSc

 

  • FDG-PET power to predict memory decline in Alzheimer’s disease depends on disease phase and amyloid and tau status

– Hanne Struyfs, MSc

 

  • Graph-Theory analysis shows a highly efficient but redundant network in MCI TAU propagation

– Sulantha Mathotaarachchi, MSc

 

  • Amyloid-Beta Modulates Cerebral Metabolic Network in Rats and Humans

  • Preclinical Assessment of Kal-ABP Target Engagement and Efficacy Using PET, MRI and CSF Biomarkers

– Min Su Kang, BSc

 

  • In vivo and in vitro demonstration of [18F]THK5351 binding to monoamine oxidase–B in the human brain

– Kok Pin Ng, MRCP